- Home
- CURR vs BMEA Comparison
CURR vs BMEA Comparison
Compare CURR & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- BMEA
- Stock Information
- Founded
- CURR 2013
- BMEA 2017
- Country
- CURR Singapore
- BMEA United States
- Employees
- CURR N/A
- BMEA N/A
- Industry
- CURR Business Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- BMEA Health Care
- Exchange
- CURR Nasdaq
- BMEA Nasdaq
- Market Cap
- CURR 133.1M
- BMEA 125.4M
- IPO Year
- CURR N/A
- BMEA 2021
- Fundamental
- Price
- CURR $1.51
- BMEA $2.13
- Analyst Decision
- CURR Strong Buy
- BMEA Buy
- Analyst Count
- CURR 1
- BMEA 13
- Target Price
- CURR $3.50
- BMEA $27.92
- AVG Volume (30 Days)
- CURR 577.0K
- BMEA 656.7K
- Earning Date
- CURR 05-11-2025
- BMEA 05-01-2025
- Dividend Yield
- CURR N/A
- BMEA N/A
- EPS Growth
- CURR N/A
- BMEA N/A
- EPS
- CURR N/A
- BMEA N/A
- Revenue
- CURR $48,723,898.00
- BMEA N/A
- Revenue This Year
- CURR N/A
- BMEA $191.34
- Revenue Next Year
- CURR N/A
- BMEA N/A
- P/E Ratio
- CURR N/A
- BMEA N/A
- Revenue Growth
- CURR N/A
- BMEA N/A
- 52 Week Low
- CURR $1.19
- BMEA $2.10
- 52 Week High
- CURR $7.08
- BMEA $16.29
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- BMEA 28.47
- Support Level
- CURR N/A
- BMEA $2.27
- Resistance Level
- CURR N/A
- BMEA $3.08
- Average True Range (ATR)
- CURR 0.00
- BMEA 0.23
- MACD
- CURR 0.00
- BMEA 0.00
- Stochastic Oscillator
- CURR 0.00
- BMEA 2.95
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.